How would you approach a patient with metastatic HR+, HER2-negative, high-grade neuroendocrine carcinoma of the breast?
How does this differ from how you treat IDC?
1 Answer
Mednet Member
Medical Oncology · Virginia Cancer Spclsts PC
Answered on
Carbo/VP16.
Join for free or sign in to see the full answer